At a glance
- Originator Millennium Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
- 05 Nov 1999 ProScript has been acquired by LeukoSite
- 14 Sep 1998 New profile